Navigation Links
Scripps Research wins more than $2 million to study prostate cancer
Date:4/26/2011

JUPITER, FL, April 26, 2011 The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

The five-year grant from the National Institutes of Health (NIH) will fund research to advance the development of novel therapeutic strategies for prostate cancer treatment and prevention.

"This new funding will help us continue our work into the origins of prostate cancer and the role that inflammation plays in its development," said Jun-Li Luo, PhD, an assistant professor on the Florida campus of Scripps Research and principal investigator for the new study. "We are pleased that Moffitt, one of the country's leading treatment and research centers, will be our partner in this research. Gaining a better understanding of the inflammatory process should help lay the foundation for developing novel therapeutic strategies for this disease."

"This collaboration with Scripps Florida is a great opportunity to help uncover the underlying mechanisms of prostate cancer," said Shohreh Dickinson, MD, an assistant professor at Moffitt, where scientists will study and interpret pathology slides of human cells as part of the new study. "It's also a great opportunity for two Florida research centers to advance the science that, hopefully, will one day help put an end to this terrible disease."

Prostate cancerwhich, according to the American Cancer Society, will affect one in six American men in their lifetimeis the second-leading cause of death after lung cancer in American men. Prostate cancer is driven by androgen, the male sex hormone, and androgen deprivation is considered a first-line treatment of the disease once it spreads beyond the prostate gland.

Eventually, all prostate cancer becomes resi
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. New lupus drug results from Scripps Research technology
2. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
3. Scripps Research study points to liver, not brain, as origin of Alzheimers plaques
4. Scripps Research compound blocks brain cell destruction in Parkinsons disease
5. Scripps Research scientists develop powerful new methodology for stabilizing proteins
6. Scripps Research scientists find measles natural nemesis
7. Scripps Research scientists awarded $2.35 million to study new obesity treatment
8. Scripps Research scientists identify first synthetic activator of 2 critical proteins
9. Scripps Clinic nurse to receive 2010 ASTRO Nurse Excellence Award
10. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
11. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Nashville, TN (PRWEB) May 20, 2013 Along ... Warren Melamed has remained a fervent proponent of regular ... appropriate brushing and flossing twice a day. While these recommendations ... of tooth decay reveal that most adults and children are ... patients must find a new way to break into the ...
(Date:5/20/2013)... Senior Solutions Management Group (SSMG), a ... Southeast, today announced that four of its Resident Assistants ... communities have received The Caring Heart Award from Alzheimer’s ... Loudon, Nicole Braden from River Oaks Place in Loudon, ... and Meghan McCormick from Wellspring Senior Living in Knoxville ...
(Date:5/20/2013)... 2013 The main objective for the present ... into a single comprehensive report. The objective was to ... this industry. Thus, it is timely to examine the ... an urgent need in the life science industry for technologies ... in a high-throughput, multiplex and low-cost way. Proteomic technologies ...
(Date:5/20/2013)... Idol lash has designed its brand new ... eyelashes in a matter of few weeks. It is completely ... an extra pack offer to help more women achieve broad ... on the Idol lash official website. , Numerous trials were ... density up to 82% in just a few weeks. According ...
(Date:5/20/2013)... The Semi Truck Accident Victims ... free service for an innocent victim of a catastrophic ... state our services are unparalleled. What this means is ... victim of a passenger vehicle involved in a semi ... Virginia, Ohio, New Jersey, Indiana, Maryland, Georgia, Nebraska, Kansas, ...
Breaking Medicine News(10 mins):Health News:New AirFloss Product Offers Oral Hygiene Innovation, Dental Professional Warren Melamed Comments 2Health News:Senior Solutions Management Caregivers Receive Caring Heart Award From Alzheimer’s Tennessee 2Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 2Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 3Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2Health News:Semi Truck Accident Victims Center Urges Family Members Of Victims Injured In A Horrific Semi Truck Accident In Any US State To Call Them First For An Unsurpassed Response 2
... swallowing the mobile phone by a 24 year women was an ... // The Blue Spring Police are investigated the incident in which ... phone during an argument with her boy friend in which she ... friend. Police got a phone call from her boyfriend that her ...
... Hewitt, the Health Secretary of the UK has imposed a ... //This move has raised doubts as to whether the private ... the NHS will be put into operation. ,The ... ?1 billion plan has been questioned by Ms Hewitt. The ...
... erythematosus (lupus) is a disease in which the body's ... the skin, joints and internal organs.// A study has ... take oral contraceptives safely without any complications like increased ... that characterize the disease. ,The study was ...
... scanner has been developed for premature and newborn babies that ... how the baby brain is working. ,Currently, there are ... Magnetic resonance imaging (MRI) can provide data on brain ... of risk. ,The alternative, ultrasound, can be performed ...
... health benefits of milk thistle, an herbal remedy employed in ... recent study highlighting the lack of evidence for its safety ... for thistle milk, with over 1 million people suffering from ... worldwide. ,The research team analyzed the results of ...
... been passed by the Food and Drug Administration (FDA) saying that ... to be mentioned in the label of the product. ... milk, eggs, fish, crustaceans, wheat, tree nuts, soybeans and peanuts. ... allergies are one of the major causes of death in US. ...
Cached Medicine News:Health News:Milk Thistle Not An Effective Cure For Liver Disease 2
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( http://www.oramed.com ... today that the United States Food and Drug Administration ... for ORMD-0801, its oral insulin capsule. "We ... proceed," stated Nadav Kidron , CEO ... for Oramed and we look forward to continuing to ...
(Date:5/16/2013)... Ill. and MECHELEN, Belgium ... GLPG) and AbbVie (NYSE: ABBV ) announced ... to include Crohn,s disease.  Galapagos will fund and complete ... designed to facilitate rapid progression into Phase 3.  Upon ... AbbVie will pay Galapagos $50 million.  The terms of ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... of Regulatory Submissions Leadership Strengthened with Clinical ... Trials Services and Standards-Based Data Management, WHIPPANY, ... (ISI) announced today it agreed to terms to ... industry moving to,standards-based regulatory submissions, the acquisition further ...
... the First Hsp90 Inhibitor to Enter Registration Trials, ... KOSN ) today announced that it has successfully,reached a ... on the design of its TIME-1 clinical trial, a ... a treatment for patients with,multiple myeloma. Through the FDA,s ...
Cached Medicine Technology:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: